|
|
|
The Bloom #143
Free Edition
Unus pro Omnibus, Omnes pro Uno
|
What can we learn from 10 years of PAT in a legal and reimbursed setting? Over 1000 patients have been treated in Switzerland since 2014, though challenges remain in the execution of PAT.
One challenge is the question of whether we need to have repeated dosings. For clinical trials, it's standard to ... well ... standardize. But an innovative trial in Canada has studied the effects of doing repeated doses in some participants and found cummulative positive effects.
Finally (at least in the highlight here, and in our Pro Research Briefing) I take a look at the third study that has been published on the use of microdosing for ADHD. The prospective survey finds positive effects, but most fall away when directly compared to conventional treatments at the final four-week mark.
Much more can be found in the other study links below as the research continues to flood my inbox.
Floris - Founder of Blossom
PS Have you been a psychedelic guide for others, formally or informally? If so, please consider collaborating in the new study by the Universities of Lisbon and Leiden, assessing perceptions of psychedelic practitioners regarding health behavior changes (e.g., physical activity, diet, and mindfulness) after psychedelic experiences. Please see the study webpage for detailed information and a link to complete the questionnaire.
Latest Psychedelic Research
This commentary provides insights into the current practice of psychedelics-assisted therapy (PAT) in Switzerland, based on legally permitted medical use since 2014. Over 1000 individual case permits have been issued, allowing approximately 2000-3000 treatments. The article discusses application procedures, treatment frameworks, and ethical considerations, highlighting the potential for integrating PAT into psychotherapy internationally while emphasizing the need for ongoing therapist education and quality assurance measures.
Unlock 2000+ Psychedelic Research Summaries with a Pro Membership
Discover a treasure trove of knowledge and support the vital coverage & advancement of psychedelic research
|
|
|
This open-label waitlist trial (n=30) assessed the feasibility of psilocybin-assisted psychotherapy (PAP/PAT) in a complex population with treatment-resistant depression (TRD), including major depressive and bipolar II disorders, baseline suicidality, and significant comorbidity. Participants received one, two, or three sessions of PAP with psilocybin (25mg), accompanied by preparation and integration psychotherapy sessions. Immediate treatment showed greater reductions in depression severity (MADRS) compared to the waitlist period, with a large effect size (g = 1.07, p < 0.01). Repeated doses were associated with further reductions in depression severity. Adverse events were transient, and the study demonstrated feasibility, preliminary antidepressant efficacy, safety, and tolerability in this population.
This prospective survey (n=233, 64, 44) explores microdosing's (MD) impact on emotional regulation (ER) and empathy in adults with severe ADHD symptoms. Positive effects on ER and empathy were observed, specifically in cognitive reappraisal, expressive suppression, perspective-taking, and personal distress. However, a comparison with those using only conventional medications (n=180, 50, 38 MD; n=37, 27, 28 conventional) revealed that after four weeks, only expressive suppression improvement persisted, and cognitive reappraisal and empathy enhancements disappeared.
More new research
|
|
|
New on Blossom
How can microdosing support people who experience ADHD, and does it work better than conventional medications? The first article explores this across two studies. We then venture into the heart of Europe, where psychedelic-assisted psychotherapy has been legally possible for the last decade (again). Finally, I’ll focus on the flexible repeated dosing in a trial with psilocybin for depression.
Gain Unparalleled Insight with Pro
Access 2000+ Research Summaries
"Blossom is democratising access to psychedelic research" - Josh Hardman
|
|
|
All the other papers that have come out this year that don't have a separate entry in the database.
Spotlight
The Self-Regulation Research Group at the Faculty of Human Kinetics (Portugal), in collaboration with Leiden University, is conducting a study to assess the perception of psychedelic practitioners about health behaviours - e.g., physical activity, diet, and mindfulness - after a psychedelic experience.
The study aims to investigate the relationship between psychedelic experiences and changes in health-related behaviours from the perception of psychedelic facilitators (or anyone who has guided others).
Participation involves filling out a 30-minute anonymous online survey. To be eligible, participants must have consumed (at least 10 times) a psychedelic substance, have guided, supported or facilitated at least 30 psychedelic experiences (individual or group experiences), be at least 18 years old and have a good understanding of English.
More details and the link to complete the questionnaire can be accessed on the study webpage.
Since 2015, Chacruna has organized large conferences in Mexico and annual spring events on the West Coast starting in 2018. The Psychedelic Culture 2024 conference will delve into pioneering topics outside the mainstream psychedelic discourse, focusing on Indigenous Reciprocity, Decolonial Dialogues, Psychedelic Justice, and the preservation of Sacred Plants and Cultural Traditions.
This two-day event features three parallel tracks, bringing together panels and hands-on sessions on Indigenous perspectives, conservation, religious and ceremonial practices with psychedelics, legal reforms, racial and gender equity, contributions from the Global South, and ethical considerations in psychedelic science and therapy.
Additionally, it will include music, meditation, and rapé ceremonies. Held at San Francisco's Brava Theater, Chacruna's conference aims to bridge the gap between scientific research and traditional knowledge holders in the psychedelic field, emphasizing community, activism, and interdisciplinary dialogue.
Use the code Blossom20 to get 20% off your tickets.
|
|
|